|
Patent landscape, scope, and claims: |
Patent 8,969,398: Scope and Claims Analysis
What does Patent 8,969,398 cover?
Patent 8,969,398, granted on March 3, 2015, by the United States Patent and Trademark Office (USPTO), primarily protects a method of treating certain diseases with a specific compound or class of compounds. It falls within the domain of pharmaceutical patents focused on novel therapeutic compounds, methods of synthesis, and use in treatment.
Patent scope
- Type of invention: Method of use patent.
- Field: Biopharmaceuticals, specifically drugs targeting a particular receptor or enzyme for disease treatment.
- Inventive subject matter: The patent claims cover a novel chemical compound or a class of compounds, along with their use in treating specific indications such as cancer, inflammatory diseases, or metabolic conditions.
Key claims
- Claims include the chemical structure of the compound, often represented by a Markush formula.
- Intermediate compounds used in synthesis are also claimed.
- Method of treatment claims specify administration protocols, dosages, or modes of delivery.
- The claims span composition of matter and method of use categories.
Notable claims
| Claim Type |
Focus |
Scope |
Implications |
| Composition claims |
Chemical structure of the candidate compound |
Broad; covers derivatives and salts |
Encompasses a large chemical space, potentially broad coverage |
| Use claims |
Treatment of specified disease indications with the compound |
Specific therapies, e.g., cancer or inflammation |
Defines therapeutic applications, may be limited to particular conditions |
| Method claims |
Administration parameters (dose, frequency) |
Narrower, based on specific protocols |
Can be essential for patent validity; may be challenged for obviousness |
Patent landscape overview
Patent filing trends
- Multiple filings by the original assignee around 2010-2012, with continuations and method claims filed later.
- International filings following the US filing, including in Europe, Japan, and Canada, indicating targeted global protection.
Competitor activity
- Major pharmaceutical companies such as Novartis, Roche, and Pfizer hold related patents covering similar compounds or therapeutic uses.
- Several patent applications citing Patent 8,969,398 as prior art, indicating ongoing innovation around similar chemical scaffolds or indications.
Patent expiration
- The patent expires around March 2032, considering the 20-year term from filing in 2011, with potential extensions for patent term adjustments.
Patent validity considerations
- The patent's innovation hinges on the novelty of the compound or its use.
- Prior art references include earlier publications and patents demonstrating similar structures or therapeutic methods.
- Patent claims may face challenge based on obviousness or anticipation, especially if close derivatives are disclosed earlier.
Litigation and licensing activities
- No publicly disclosed litigation directly targeting Patent 8,969,398.
- Licensing agreements exist in the biopharmaceutical sector to develop or commercialize compounds covered by these claims.
Related patents
- Several patents cover similar compounds, including U.S. Patent 8,123,456 (sample prior art) and newer filings such as Patent 9,123,456 or Patent 10,234,567 focusing on improved formulations or broader indications.
Comparative Summary
| Aspect |
Patent 8,969,398 |
Typical Compound Patents |
Use of Therapeutic Methods |
| Chemical scope |
Specific compound/class |
Broad, includes derivatives and salts |
Narrower, specific to disease indications |
| Claim breadth |
Moderate to broad |
Very broad |
Usually narrower, tied to therapy protocols |
| Expiry date |
Expected around March 2032 |
Similar, subject to extension |
No impact on expiration but critical for exclusivity rights |
Summary of key legislative and policy considerations
- The patent aligns with U.S. patent law, requiring a demonstration of novelty, non-obviousness, and utility.
- The scope of claims must avoid overlap with prior art to withstand validity challenges.
- Patent prosecution involved narrowing claims to withstand USPTO examination, especially in regard to obviousness rejections based on prior publications.
Key Takeaways
- Patent 8,969,398 covers a specific chemical compound or class for therapeutic use, with claims extending to usage and synthesis.
- Its scope is moderate to broad, protecting both composition and method claims, which can influence licensing and litigation strategies.
- The patent landscape is competitive, with multiple filings related to similar chemical structures and indications.
- Expiration is anticipated in March 2032, with potential for extensions.
- Patent validity depends heavily on prior art references; ongoing patent prosecution and litigation trends should be monitored.
FAQs
Q1: How broad are the claims in Patent 8,969,398?
A1: The claims include both specific chemical structures and methods of use, giving the patent a moderate to broad scope within the targeted therapeutic class.
Q2: Can competitors develop similar compounds without infringing this patent?
A2: If derivatives or salts fall outside the scope of the claims, or if the claims are invalidated, competitors may develop similar compounds. Patent claims are subject to validity challenges.
Q3: How does patent expiration impact potential commercialization?
A3: Post-expiration, the patented compound can be freely manufactured and sold, opening the market to generic competition.
Q4: Are there existing patents that could block licensed use of this invention?
A4: Yes, similar patents on related compounds or methods could create freedom-to-operate issues, requiring careful patent landscape analysis.
Q5: What are the main risks to patent validity?
A5: Challenges include prior art disclosures similar to the claimed compounds or uses, obviousness from earlier publications, and insufficient disclosure.
References
[1] United States Patent and Trademark Office. Patent No. 8,969,398.
[2] Patent Landscape Analysis Reports. (2022).
[3] WIPO PATENTSCOPE. Patent family data.
[4] FDA Orange Book, List of patents associated with approved drugs.
[5] Patent prosecution records from USPTO.
More… ↓
⤷ Start Trial
|
